Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NicOx and Ferrer Grupo International have said that the Phase I results for a novel, high potency, nitric oxide-donating anti-inflammatory prototype compound show the potential for improved safety and tolerability, suggesting it could have enhanced anti-inflammatory activity over current dermatology products.
Subscribe to our email newsletter
NicOx and Ferrer initiated their development program focused on high potency, nitric oxide-donating anti-inflammatory agents, for the treatment of a range of skin disorders.
Ennio Ongini, vice president of research, NicOx, said: “These results highlight the potential of our technology in dermatology and suggest our joint program with Ferrer has the potential to provide more effective drugs to treat chronic skin disorders, which represent an increasing burden on medical services. Furthermore, the clinical data on NCX 1022 suggest that nitric oxide donation may also improve the safety margin over current treatments. We will continue to work closely with Ferrer to bring our promising drug candidate into clinical trials.”
Antonio Guglietta, head of R&D at Ferrer, said: “Nitric oxide is thought to play an important role in the physiology of the skin and these new preclinical results suggest nitric oxide-donating anti-inflammatory agents could have improved efficacy over existing treatments. We believe this collaboration with NicOx can lead to the successful development of a more effective and safer treatment for skin disorders.”